NR3C2 and hydrops fetalis: The action of MRAs in preventing aldosterone through competitive association with mineralocorticoid receptors is proving to be an effective complementary drug to ACEi for patients with HF, thus making MRAs one of the four classes of drugs used in the treatment of heart failure (26).